Pathogen reduction using riboflavin and UV light is a method by which infectious pathogens in blood for transfusion are inactivated by adding riboflavin and irradiating with UV light. This method reduces the infectious levels of disease-causing agents that may be found in donated blood components, while still maintaining good quality blood components for transfusion. This type of approach to increase blood safety is also known as “pathogen inactivation” in the industry. Despite measures that are in place in the developed world to ensure the safety of blood products for transfusion, a risk of disease transmission still exists. Consequently, the development of pathogen inactivation/reduction technologies for blood products has been an ongoing effort in the field of transfusion medicine. A new procedure for the treatment of individual units of single-donor or whole blood–derived, pooled, platelets has recently been introduced. This technology uses riboflavin and light for the treatment of platelets and plasma.
Method
This pathogen reduction process involves adding riboflavin to the blood component, which is then placed into an illuminator where it is exposed to UV light for about five to ten minutes. Exposure to UV light activates riboflavin and when it is associated with nucleic acids, riboflavin causes a chemical alteration to functional groups of the nucleic acids thereby making pathogens unable to replicate. In this way the process prevents viruses, bacteria, parasites and white blood cells, from replicating and causing disease. This method using riboflavin and UV light renders pathogens harmless by using a non-mutagenic, non-toxic method. Riboflavin and its photoproducts are already present in the human body and do not need to be removed from blood products prior to transfusion.
Bacteria – such as: B. cereus, E. cloacae, E. coli, K. pneumonia, P. acnes, S. marcescens, S. aureus, S. epidermidis, S. agalactiae, S. mitis, S. pyogenes, and Y. enterocolitica.
The riboflavin and UV light method for pathogen reduction of platelets and plasma is in routine use in multiple countries throughout Europe. This same process is currently in development for the treatment of whole blood, resulting in pathogen reduction of the three components.
